I am pleased to give a quick update on the trial, which is going well. Four patients who have been severely affected by retinitis pigmentosa have been enrolled at each of our clinical sites: the Gavin Herbert Eye Institute at UCI and Retina Vitreous Associates (RVA), for a total eight patients. Our independent Data Safety Monitoring Board has reviewed the interim results and has no safety concerns. We look forward to enrolling the next group of patients through our clinical sites and providing further updates as the trial progresses.
Henry Klassen, MD, PhD
November 18, 2015